2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Cytoskeleton
  4. Microtubule/Tubulin

Microtubule/Tubulin

Microtubule/Tubulin

Related Products

PDF 0.04 MB

Microtubules are a component of the cytoskeleton, found throughout the cytoplasm. These tubular polymers of tubulin can grow as long as 50 micrometres, with an average length of 25 µm, and are highly dynamic. The outer diameter of a microtubule is about 24 nm while the inner diameter is about 12 nm. Microtubules are found in eukaryotic cells and are formed by the polymerization of a dimer of two globular proteins, alpha and beta tubulin. Tubulin is one of several members of a small family of globular proteins. The tubulin superfamily includes five distinct families, the alpha-, beta-, gamma-, delta-, and epsilon-tubulins and a sixth family which is present only in kinetoplastid protozoa. The most common members of the tubulin family are α-tubulin and β-tubulin, the proteins that make up microtubules. Microtubules are very important in a number of cellular processes. They are involved in maintaining the structure of the cell.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-111187
    KX2-361
    		Inhibitor 99.55%
    KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell.
    KX2-361
  • HY-156423
    Tubulin/JAK2-IN-1
    		Inhibitor 99.14%
    Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells.
    Tubulin/JAK2-IN-1
  • HY-16196
    ENMD-1198
    		Inhibitor 98.87%
    ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.
    ENMD-1198
  • HY-129126
    NC9
    		99.98%
    NC9 (Cbz-Lys(Acr)-PEG2-dansyl) is an irreversible transglutaminase (TG) inhibitor. NC9 inhibits osteoblast differentiation and mineralization. NC9 destabilizes microtubules. NC9 can be used for the research of osteoblast differentiation.
    NC9
  • HY-145627
    Ozuriftamab vedotin
    		Inhibitor 99.65%
    Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities.
    Ozuriftamab vedotin
  • HY-163737
    ST-401
    		Inhibitor 99.41%
    ST-401, a microtubule-targeting agent (MTA), is a brain-penetrant microtubule (MT) assembly inhibitor. ST-401 disrupts microtubule (MT) function through gentle and reverisible reduction in MT assembly that triggers mitotic delay and cell death in interphase. ST-401 shows a potent antitumor activity.
    ST-401
  • HY-118452
    cis-3,4',5-Trimethoxy-3'-hydroxystilbene
    		Inhibitor 99.59%
    cis-3,4',5-Trimethoxy-3'-hydroxystilbene is a stilbene. cis-3,4',5-Trimethoxy-3'-hydroxystilbene induces cytochrome c release to the cytoplasm. cis-3,4',5-Trimethoxy-3'-hydroxystilbene-induced apoptosis is associated with mitochondrial release of cytochrome c. cis-3,4',5-Trimethoxy-3'-hydroxystilbene also suppresses tubulin polymerization. cis-3,4',5-Trimethoxy-3'-hydroxystilbene can be used for leukemic research.
    cis-3,4',5-Trimethoxy-3'-hydroxystilbene
  • HY-15740
    Mc-MMAD
    		Inhibitor 98.39%
    Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a agent-linker conjugate for ADC.
    Mc-MMAD
  • HY-141606
    Anetumab ravtansine
    		Inhibitor 99.36%
    Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models.
    Anetumab ravtansine
  • HY-148128
    TAM470
    		Inhibitor 98.53%
    TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity.
    TAM470
  • HY-12033S2
    2-Methoxyestradiol-d5
    		Inhibitor 98.67%
    2-Methoxyestradiol-d5 is the deuterium labeled 2-Methoxyestradiol. 2-Methoxyestradiol (2-ME2), an orally active endogenous metabolite of 17β-estradiol (E2), is an apoptosis inducer and an angiogenesis inhibitor with potent antineoplastic activity. 2-Methoxyestradiol also destablize microtubules. 2-Methoxyestradio, also a potent superoxide dismutase (SOD) inhibitor and a ROS-generating agent, induces autophagy in the transformed cell line HEK293 and the cancer cell lines U87 and HeLa.
    2-Methoxyestradiol-d<sub>5</sub>
  • HY-19916
    Lisavanbulin
    		Inhibitor 99.24%
    Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator. Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma.
    Lisavanbulin
  • HY-123283
    OXi8007
    		Inhibitor 99.35%
    OXi8007 is a water-soluble phosphate proagent of OXi8006, a tubulin-binding compound.
    OXi8007
  • HY-145734
    AMXI-5001
    		98.25%
    AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors.
    AMXI-5001
  • HY-P99334
    Vorsetuzumab mafodotin
    		Inhibitor 99.69%
    Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity.
    Vorsetuzumab mafodotin
  • HY-145989A
    Aminobenzenesulfonic auristatin E TFA
    		Inhibitor 99.39%
    Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.
    Aminobenzenesulfonic auristatin E TFA
  • HY-121524
    DJ101
    		Inhibitor 99.36%
    DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research.
    DJ101
  • HY-15575S
    VcMMAE-d8
    		Inhibitor
    VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
    VcMMAE-d<sub>8</sub>
  • HY-164835
    VcMMAE-Deruxtecan
    		Inhibitor 98.10%
    VcMMAE-Deruxtecan is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for ADC synthesis.
    VcMMAE-Deruxtecan
  • HY-15482
    D-64131
    		Inhibitor 98.98%
    D-64131 is an orally active tubulin inhibitor, with an IC50 of 0.53 μM for tubulin polymerization. D-64131 has antimitotic activity. D-64131 can be used for cancer research.
    D-64131
Cat. No. Product Name / Synonyms Application Reactivity